VHL gene fragment analysis: large inversion detection in Alu region for clinical applications Authors: Ryan N Baugher, Stephanie D Mellott, Kristen M Pike, Todd B Young, Heidi E Lawhorn, Stephen M Hewitt Published: 2026 ABSTRACT Abstractvon Hippel-Lindau (VHL) is an autosomal-dominant tumour susceptibility disorder associated with pathogenic germline variants in the VHL gene that put patients at increased risk of developing benign and malignant tumours within various organs. While current CLIA (Clinical Laboratory Improvement Amendments) genetic tests demonstrate a high detection rate of pathogenic VHL variants, clinical manifestations of VHL with atypical germline alteration undetectable by established genetic tests have been reported by Vocke et al, indicating the need for bespoke methods confirming germline alterations. We CLIA-validated a test using PCR and fragment analysis that evaluates a pathogenic inversion of 291 kb found within intron 2 of VHL and the 3′ UTR of TTLL3 in patients with canonical VHL manifestations and no conventional germline alterations. Validation results matched as expected by achieving 100% concordance. Although clinical diagnosis of VHL is possible in the absence of conclusive pathogenic cause, this report demonstrates bespoke CLIA methodologies are essential for managing hereditary diseases and promoting early symptom detection. Our CLIA assay allows for greater confidence in diagnosis for families dealing with complex structural germline alterations and may aid in future efforts at corrective therapies to ease patient suffering. This work was performed in our CLIA-certified laboratory (CLIA ID # 21D0947274).Keywords: Clinical Laboratory Techniques; Gene Rearrangement; Genetic Diseases, Inborn; Genetics; Human Genetics Overview von Hippel-Lindau (VHL) is an autosomal-dominant hereditary multisystem tumour susceptibility disorder associated with pathogenic germline variants in the VHL gene.1 Patients with VHL are at increased risk of developing multiple benign and malignant tumours within various organs, including renal cysts and central nervous system haemangioblastomas, among other outcomes.2 While current CLIA (Clinical Laboratory Improvement Amendments)-based genetic tests demonstrate a high detection rate of pathogenic germline variants in patients with VHL,3 non-syndromic and clinical manifestations of VHL with atypical germline alteration undetectable by established genetic tests have been reported with a prevalence of 20%,2 4 indicating a need for more bespoke methods for germline testing and diagnostic confirmation, especially for structural variants which have been shown to comprise between 16.6% and 25%.5 6 Recently, Vocke et al identified a novel pathogenic germline tail-to-tail inversion of 291 kb found within Alu repeats, AluYa5 in intron 2 of VHL and AluY of the 3′ untranslated region (UTR) of Tubulin Tyrosine Ligase Like 3 (TTLL3) transcript ENST00000455274, within a large family with canonical VHL manifestations and no germline alteration detected by conventional testing.2 While Vocke et al elucidated the mutation via customised testing, a CLIA-based test was still needed to identify the germline pathogenic cause for familial disease management. Here, we describe an augmented procedure to the testing previously described,2 a PCR and fragment analysis assay that evaluates inversion status of the affected family of the reported TTLL3-VHL inversion. The development of this new fragment analysis target on a previously validated CLIA platform offers a determinant for genotype of the inversion, which spans 291 kb of exons 2 and 3 of the VHL gene on chromosome 3, and now offers a fully validated assay for diagnostic use. This work was performed in our CLIA-certified laboratory (CLIA ID # 21D0947274). Patient recruitment Participants provided written consent to enroll in the natural history study 89C0086 Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders, which tracks disease progression across an individual’s lifetime and documents standard-of-care treatments used to manage von Hippel-Lindau (VHL) disease. A goal of the protocol is to investigate the genetic changes involved in cancers associated with VHL disease. Methods Primers (Invitrogen) were designed targeting the TTLL3-VHL inversion, as well as the wild-type VHL region, as shown in table 1. Previously characterised genomic DNA was used for control samples within the assay. Two master mixes were made consisting of 1.25 µL 10 µM forward primer, 1.25 µL 10 µM reverse primer, 12.5 µL 2X Platinum SuperFi PCR Master Mix (Invitrogen), 5 µL molecular biology-grade water (Lonza) and 5 µL 0.5 ng/µL-20 ng/µL DNA template. Each sample was set up with both primer sets. Reactions were amplified using an Applied Biosystems ProFlex thermal cycler at 98°C for 30 s; followed by 10 cycles of 98°C for 10 s, 62°C for 10 s and 72°C for 30 s; then 30 cycles of 98°C for 10 s, 60°C for 10 s and 72°C for 30 s; then a cycle at 72°C for 5 min followed by a 4°C hold. QC was performed using the Agilent Bioanalyzer 2100 DNA 1000 and Agilent TapeStation 4200 D1000 kits. Table 1Primer sequences for PCR and fragment analysis of the VHL wild-type region and the previously observed TTLL3-VHL inversionPrimer namePrimer sequenceVHL wild-type forward5′-HEX-GGATACCCAATTCAGTTGTAC-3′VHL wild-type reverse5′-TAGTTTTGGGGTGGTAGTCAC-3′TTLL3-VHL inversion forward5′-FAM-TGGAAGTCTGTCTTGTGCTAC-3′TTLL3-VHL inversion reverse5′-GGATACCCAATTCAGTTGTAC-3′TTLL3, Tubulin Tyrosine Ligase Like 3; VHL, von Hippel-Lindau. Primer sequences for PCR and fragment analysis of the VHL wild-type region and the previously observed TTLL3-VHL inversion TTLL3, Tubulin Tyrosine Ligase Like 3; VHL, von Hippel-Lindau. Reaction volumes for the TTLL3-VHL inversion and VHL wild type were combined in a 1:1 ratio. Fragment analysis was performed with a master mix of 8.5 µL HiDi Formamide (Applied Biosystems) and 0.5 µL LIZ 500 size standard (Applied Biosystems). To this, 1 µL of combined reaction product, appropriately diluted with molecular biology-grade water (Lonza) to prevent signal saturation, was added. Denaturation occurred at 95°C for 5 min, then rapid-cooled on a cold block for 2 min. Reactions were then loaded onto either 3730XL or SeqStudio 24 Flex Genomic analyzers (Thermo Fisher Scientific) for capillary electrophoresis on a 50 cm array using POP-7 polymer (Applied Biosystems) and the preset FragmentAnalysis50_POP7 run modules on each respective instrument. Analysis was performed using GeneMapper V.5 software (Applied Biosystems). Fragment analysis plots and sizing tables were established from instrument-generated fsa and ser files. Samples determined to be negative for the inversion produced fragment sizes of 381–385 bp in the green dye spectra; samples deemed to be homozygous mutant for the inversion produced fragment sizes of 362–365 bp in the blue dye spectra; and samples deemed heterozygous for the inversion showed both peak sets mentioned above. Example plot images and corresponding quality control (QC) display from Bioanalyzer and TapeStation are shown in figure 1. Quality control (QC) images and fragment analysis plot images for the von Hippel-Lindau (VHL) wild-type and Tubulin Tyrosine Ligase Like 3 (TTLL3)-VHL inversion amplicons. QC images (A–B) show Bioanalyzer data run for the VHL wild-type assay (A) and the TTLL3-VHL inversion assay (B) on an Agilent DNA 1000 kit for a no-template control, a sample heterozygous for the inversion and a sample homozygous wild type, alongside the kit-provided ladder. The fragment analysis plots (C–D) show a sample heterozygous for the TTLL3-VHL inversion (C) and homozygous for VHL wild type (D). Blue peaks (6-Carboxyfluorescein; FAM) represent the TTLL3-VHL assay, green peaks (Hexachlorofluorescein; HEX) represent the VHL wild-type assay, and orange peaks represent LIZ500 size standard used in the assay. Bridging study Per CLIA regulations, since other standard PCR and fragment analysis workflows were previously validated in our laboratory using a blinded sample set of 21 and testing for accuracy, precision, reportable range, reference range analytical specificity and analytical sensitivity, the VHL assay went through a brief bridging study. Due to minimally reported presence of the reported inversion, four samples were tested twice for the VHL inversion, with two samples known to have the inversion and two known to have wild-type presentation. Samples were amplified, checked for size and concentration on a Bioanalyzer 2100 or TapeStation 4200, and had fragment analysis performed to determine presence/absence of wild-type amplicon and mutant inversion amplicon peaks. Amplicons were also Sanger sequenced and alignment of the sequence to wild type and inversion reference sequence performed to ensure proper unique product was generated. Samples were either positive for wild type VHL and positive for the inversion site in TTLL3-VHL, or positive for wild-type VHL and negative for the inversion site in TTLL3-VHL. All results matched as expected by achieving 100% concordance. Discussion As previously described,2 the nature of this inversion event prevents detection by karyotype analysis, highlighting the need for genetic testing to confirm the rearrangement. Our assay varies slightly from that of the Vocke et al publication in 2024,2 incorporating fragment analysis for a more confident diagnostic output allowing for demonstration of homozygous or heterozygous status. We’ve also bridged this assay by CLIA guidelines, enabling this accurate, rapid and inexpensive test to be used for generating diagnostic data to potentially diagnose VHL disorder with atypical germline presentation. While this fragment analysis assay presents a specifically targeted approach that prevents broad applicability, it does fill a diagnostic need. Broader sequencing modalities such as whole genome sequencing address a wider range of VHL variants, including de novo mutations. However, typical short read sequencing methods prevent proper contig mapping that would elucidate the 291 000 bp alteration targeted here, as these technologies typically struggle with resolution of structural variants larger than 50 bp due to inability to determine orientation of the contigs,7 complicated further by Alu sites within the region, requiring alternative methods. Long read sequencing addresses these drawbacks to bridge this gap clinically but often via cost-prohibitive methods8 that do not currently suit the needs for bespoke conditions as described here. Since CLIA validation, to date, no adult patients have tested positive without also exhibiting clinical manifestations and have shown clinical symptoms prior to testing. However, due to the hereditary nature of the disease, children within the family were tested without clinical symptoms at the time of testing. The VHL assay identified minors who tested positive for the inversion without clinical features, and surveillance was initiated due to positive results, and disease-related lesions were subsequently detected during monitoring. The test enabled these children to begin surveillance at an earlier stage of their disease, potentially improving life expectancy, quality of life and helping to prevent life-altering surgeries that other adult family members experienced due to the prior unavailability of this test. This report highlights the need for evolving methodologies and valuable bespoke assays in a clinical space to evaluate alterations in patients with hereditary diseases whose needs may not be met by standard processing modalities. While conventional testing offers elucidation for the vast majority of VHL patients who will have germline variants, this familial 291 kb inversion highlights the need for germline structural variants to be considered in the absence of other genetic causes.1 2 Although clinical diagnosis of diseases such as VHL is possible in the absence of conclusive pathogenic causes, identifying the germline cause is an essential component of managing hereditary disease, allowing for the identification of non-symptomatic family members to more appropriately screen and surveil for improved care and early symptom detection. Given this need for diagnosis of atypical structural germline alterations, our assay, validated by CLIA requirements, fills a niche in the field allowing for greater confidence in diagnosis and disease management for families such as these2 dealing with a complex genetic component to their disease state and may aid in future efforts at corrective therapies that could ease patient suffering. Acknowledgements We thank Dr Daniel Soppet and Dr William Bocik for their support in process development and clinical validation discussions. Thank you to our collaborators within the NCI Tissue Processing and Sequencing Facility for their insight during meetings and provision of samples for validation and optimisation testing. Thanks to Lidenys O’Brien for assistance with information regarding patient consent and recruitment. Footnotes Funding: This project has been funded in whole or in part with Federal funds from the NCI, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91019D00024. The content of the publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and was approved by the NCI institutional review board and was performed under protocol NCI-89-C-0086. Participants gave informed consent to participate in the study before taking part. Provenance and peer review: Not commissioned; externally peer reviewed. References